愛齊科技 (ALGN) 2026 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings. Welcome to the Align second quarter 2026 earnings call. (Operator Instructions) Please note, this conference is being recorded. I will now turn the conference over to your host, Shirley Stacy with Align Technology. You may begin.

    各位好。歡迎參加 Align 2026 年第二季財報電話會議。(接線員指示) 請注意,本次會議將被錄音。現在我將把會議交給本次主持人、Align Technology 的 Shirley Stacy。您可以開始了。

  • Shirley Stacy - Vice President, Finance, Corporate and Investor Communications

    Shirley Stacy - Vice President, Finance, Corporate and Investor Communications

  • Good afternoon and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued second quarter 2026 financial results today via Business Wire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 1 month.

    各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的還有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們今天已透過 Business Wire 發布 2026 年第二季財務結果,並可於我們網站 investor.aligntech.com 查閱。今天的電話會議將以音訊網路直播,並會在我們網站上存檔約 1 個月。

  • As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events, product outlook and financial expectations. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements.

    提醒各位,今天提供與討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望與財務預期的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近期向美國證券交易委員會提交的定期報告中有更詳細說明,報告可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。

  • We have posted historical financial statements with corresponding reconciliations, including our GAAP to non-GAAP reconciliation, if applicable, and our second quarter 2026 conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.

    我們已在網站「季度業績」專區張貼歷史財務報表及相應調節表(如適用,包括 GAAP 與非 GAAP 的調節),以及 2026 年第二季電話會議簡報。如需更詳細資訊,請參閱這些檔案。

  • With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

    接下來,我將把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?

  • Joseph Hogan - President, Chief Executive Officer, Director

    Joseph Hogan - President, Chief Executive Officer, Director

  • Thanks, Shirley. Good afternoon, and thank you for joining us today. On today's call, I'll start with an overview of our second quarter 2026 results, discuss performance across our two operating segments, Clear Aligners and Systems and Services. John will then walk you through our financial results and outlook for Q3 and 2026. And after that, I'll come back and highlight a few key takeaways before we open the call for questions.

    謝謝你,Shirley。各位下午好,感謝今天加入我們。在今天的電話會議中,我將先概述 2026 年第二季業績,並討論我們兩個營運部門——透明牙套(Clear Aligners)以及系統與服務(Systems and Services)的表現。接著 John 將帶各位檢視我們的財務結果,以及對第三季與 2026 年全年的展望。之後我會回來強調幾項重點,然後開放提問。

  • We delivered a solid second quarter with record revenues of $1.06 billion, up 4.3% year-over-year, driven by record Clear Aligner volumes of 692,000 cases and 8.2% Clear Aligner revenue growth. Q2 '26 revenues and Clear Aligner volumes were in line with our outlook, while Clear Aligner ASPs and non-GAAP operating margin of 22.9% exceeded our expectations. Q2 '26 year-over-year Clear Aligner volume growth of 7.4% was driven by continued double-digit expansion across APAC, EMEA and Latin America, together with stable performance in North America. Growth reflected continued adoption across orthodontists and GP dentist channels and across adult, teen and growing patient segments as well as continued double-digit growth from our DSOs.

    我們在第二季交出穩健成績,營收創新高達 10.6 億美元,年增 4.3%,主要由透明牙套出貨量創新高 69.2 萬例,以及透明牙套營收年增 8.2% 所帶動。2026 年第二季營收與透明牙套出貨量符合我們的展望,而透明牙套 ASP(平均售價)及非 GAAP 營業利益率 22.9% 則優於預期。2026 年第二季透明牙套出貨量年增 7.4%,主要來自亞太(APAC)、歐洲中東非洲(EMEA)與拉丁美洲持續雙位數擴張,加上北美表現穩定。成長反映矯正專科醫師與一般牙醫(GP)通路的持續採用,以及成人、青少年與成長中患者族群的擴張,同時我們的 DSO(牙科服務組織)亦維持雙位數成長。

  • Investments in patient financing, clinical support programs, doctor subscription offerings and practice productivity solutions supported adoption and utilization across our global Invisalign business. In Systems and Services, Q2 '26 revenue performance reflected persistent softness in the capital equipment market as well as a shift toward lower-priced scanners and flexible acquisition models, including leasing and rental programs, which generate lower upfront revenue than traditional scanner purchases.

    我們在患者融資、臨床支援計畫、醫師訂閱方案與診所生產力解決方案上的投資,支持了全球 Invisalign 業務的採用與使用率提升。在系統與服務方面,2026 年第二季營收表現反映資本設備市場持續疲弱,以及市場轉向較低價格掃描器與更彈性的取得模式(包括租賃與租用方案);相較於傳統掃描器購買,這些模式帶來較低的前期營收。

  • Overall, second quarter results reflect continued execution against a volatile macroeconomic backdrop. While the environment created some noise in the quarter, the underlying momentum in business driven by ongoing investments in innovation, customer engagement and digital workflows continue to support improvements in practice productivity, patient conversion and treatment adoption.

    整體而言,第二季結果反映我們在波動的總體經濟背景下持續落實執行。雖然環境在本季帶來一些雜訊,但在創新、客戶互動與數位工作流程的持續投資所驅動下,業務的基本動能仍在,並持續支持診所生產力、患者轉化率與治療採用率的改善。

  • For imaging systems and CAD/CAM systems and services, including iTero, exocad and X-ray Insight software, Q2 revenue of $185.3 million was down 11% year-over-year as a result of lower scanner ASPs, partially offset by double-digit growth in unit placements, driven by continued challenges in the capital equipment market with higher interest rates and increased macro uncertainty. We continue to lower the total acquisition cost of and expand access to intraoral scanning by offering doctors a range of purchasing options for iTero Lumina scanner that best fits the needs, budgets and cash flows of our customers, including low-cost configurations such as iTero Lumina PC and certified preowned scanners and rental and lease programs.

    在影像系統以及 CAD/CAM 系統與服務(包括 iTero、exocad 與 X-ray Insight 軟體)方面,第二季營收為 1.853 億美元,年減 11%,主因掃描器 ASP 較低;部分被單位裝機量(unit placements)雙位數成長所抵銷。資本設備市場在較高利率與總體不確定性升高下仍面臨持續挑戰。我們持續透過提供多元購買選項,降低口內掃描的總取得成本並擴大可及性,讓醫師可選擇最符合其需求、預算與現金流的 iTero Lumina 掃描器方案,包括 iTero Lumina PC 等低成本配置、認證二手機,以及租用與租賃方案。

  • Importantly, while growing adoption of these purchasing options creates a near-term headwind to reported revenue and profitability, this is an intentionally and strategically attractive evolution of the business. By lowering the upfront cost of adoption, we can expand access to care, grow reoccurring revenue and strengthen the Align Digital Platform.

    重要的是,雖然這些購買選項的採用增加,短期內會對已報告的營收與獲利能力造成逆風,但這是我們有意為之、且在策略上具吸引力的業務演進。透過降低採用的前期成本,我們能擴大照護可及性、提升經常性收入,並強化 Align 數位平台。

  • We're already seeing the benefits of this strategy. During Q2, scanner placements to new doctors reached a record level and increased double digits year-over-year, driven by continued adoption of iTero Lumina. Active scanner units also grew double digits year-over-year, while more than 12.4 million restorative wellness and orthodontic scans were performed during the quarter, an increase of 16% year-over-year. Healthy scanner placements, growth in active units and increasing digital workflow utilization to support communications between doctors and patients to improve patient oral health and aesthetics and strengthen the connection between diagnostics, treatment planning, restorative workflows, orthodontic treatments, including clear aligner adoption.

    我們已經看到此策略帶來的效益。在第二季,對新醫師的掃描器裝機量創下新高,且年增達雙位數,主要由 iTero Lumina 的持續採用所帶動。啟用中的掃描器台數亦年增雙位數;本季完成超過 1,240 萬次修復健康與矯正掃描,年增 16%。健康的裝機量、啟用台數成長,以及數位工作流程使用率提升,有助於支援醫師與患者之間的溝通,改善患者口腔健康與美觀,並強化診斷、治療規劃、修復工作流程與矯正治療(包括透明牙套採用)之間的連結。

  • Our exocad CAD/CAM business delivered double-digit year-over-year revenue growth in Q2, reinforcing our strategy to expand access to care by seamlessly integrating orthodontics and restorative dentistry across the Align digital platform. During the quarter, exocad hosted its flagship Insights 2026 event, bringing together more than 850 dental professionals from over 44 countries, and launched exocad ART which means Advanced Restorative Treatment, which combines tooth alignment and restorative treatments within the exocad software to offer more doctors and patients more comprehensive treatment options.

    我們的 exocad CAD/CAM 業務在第二季實現年增雙位數的營收成長,進一步印證我們透過 Align 數位平台無縫整合矯正與修復牙科、以擴大照護可及性的策略。本季 exocad 舉辦其旗艦活動 Insights 2026,匯聚來自 44 個以上國家的 850 多位牙科專業人士,並推出 exocad ART(Advanced Restorative Treatment,先進修復治療),在 exocad 軟體中結合牙齒排列與修復治療,為更多醫師與患者提供更全面的治療選項。

  • Q2 '26 clear aligner shipments reached a record 692,000 cases, increasing 7.4% year-over-year. Growth was broad-based across customer channels, patient segments and geographies, reflecting continued adoption of the Invisalign System and benefits of our strategic initiatives to improve affordability, patient conversion, clinical confidence and practice productivity. Growth was supported by both increased doctor adoption and higher utilization.

    2026 年第二季透明牙套出貨量達到創紀錄的 69.2 萬例,年增 7.4%。成長在客戶通路、患者族群與地理區域上皆呈現廣泛分布,反映 Invisalign 系統的持續採用,以及我們在提升可負擔性、患者轉化、臨床信心與診所生產力等策略性措施所帶來的效益。成長同時受惠於醫師採用增加與使用率提升。

  • During the quarter, a record 89,200 doctors submitted Invisalign cases, up globally 3.4% year-over-year, while doctor utilization increased 3.8%, reflecting growth across all regions. Shipments to orthodontists increased 7.8% year-over-year, and shipments to GP dentists increased 6.6%, demonstrating ongoing momentum across both customer channels. Regionally, growth was led by our international markets in EMEA and APAC.

    本季共有創紀錄的 89,200 位醫師提交 Invisalign 病例,全球年增 3.4%;同時醫師使用率提升 3.8%,反映各區域皆有成長。對矯正專科醫師的出貨量年增 7.8%,對一般牙醫(GP)的出貨量年增 6.6%,顯示兩大客戶通路皆持續具動能。就區域而言,成長主要由 EMEA 與 APAC 等國際市場帶動。

  • Both delivered double-digit volume growth driven by increased utilization across doctor channels and patient segments, while Latin America delivered record second quarter shipments supported by increased submitters and higher utilization. North America remained relatively stable overall with continued strength in orthodontic and DSO channels helping to offset slower retail demand.

    兩者皆實現雙位數的出貨量成長,主要由醫師通路與患者族群的使用率提升所驅動;拉丁美洲則在提交醫師數增加與使用率提高的支持下,第二季出貨量創下新高。北美整體維持相對穩定,矯正專科與 DSO 通路的持續強勁表現,有助於抵銷零售需求較慢的影響。

  • Our growth initiatives continue to gain traction across orthodontists, GP dentists and DSO investments, and financing, clinical support, workflow solutions and practice productivity tools are helping doctors increase utilization, improve patient conversion and expand access to treatment. Adoption of programs such as DSP, patient financing solutions and Comp Zero AA, which are designed to support practice growth while improving affordability and access to patients, remain encouraging.

    我們的成長計畫在矯正專科醫師、一般牙醫(GP)與 DSO 方面持續取得進展;而融資、臨床支援、工作流程解決方案與診所生產力工具,正協助醫師提升使用率、改善患者轉化並擴大治療可及性。DSP、患者融資解決方案與 Comp Zero AA 等計畫的採用(其設計旨在支持診所成長,同時提升患者的可負擔性與可及性)仍令人鼓舞。

  • For teens and growing patients, treatment starts increased 7.2% year-over-year to 240,000 Invisalign cases led by China, Japan, Turkey, India and Brazil. Continued adoption of Invisalign First, the Invisalign palate expander Invisalign MOAB, Mandibular Advancement with Occlusal Blocks, reflects greater doctor confidence in our growing patient portfolio and reinforces the significant long-term opportunity we see in these categories.

    針對青少年與成長期患者,治療啟動量年增 7.2% 至 240,000 例 Invisalign 病例,主要由中國、日本、土耳其、印度與巴西帶動。Invisalign First、Invisalign 腭擴弓器(palate expander)以及 Invisalign MOAB(Mandibular Advancement with Occlusal Blocks,帶咬合塊的下顎前移)持續被採用,反映醫師對我們成長期患者產品組合的信心提升,並強化我們在這些類別所看到的顯著長期機會。

  • We recently introduced two new capabilities across the Align Digital Platform designed to improve patient engagement, treatment planning and workflow efficiency. Together with the Invisalign palate expander platform, integrated buttons, custom trim lines and specific 3D printed attachments, these capabilities strengthen the connection between imaging, diagnostics, treatment planning and treatment delivery through a more integrated digital workflow.

    我們近期在 Align 數位平台(Align Digital Platform)推出兩項新功能,旨在提升患者互動、治療規劃與工作流程效率。結合 Invisalign 腭擴弓器平台、整合式按鈕(integrated buttons)、客製修邊線(custom trim lines)以及特定 3D 列印附件(attachments),這些功能透過更整合的數位工作流程,強化影像、診斷、治療規劃與治療交付之間的連結。

  • We featured these innovations this past weekend at the 2026 Invisalign Ortho Summit, our premier peer-to-peer clinical education event where we brought together our innovations to life, demonstrating how we leverage software, visualization, digital treatment planning and 3D printing and workflow connectivity to explain clinical applicability, enhance practice productivity and strengthen customer engagement.

    我們在上週末的 2026 Invisalign Ortho Summit(我們最重要的同儕臨床教育活動)展示了這些創新,將創新具體呈現,示範我們如何運用軟體、視覺化、數位治療規劃、3D 列印與工作流程連結性,來說明臨床適用性、提升診所生產力並強化客戶互動。

  • Before turning to John, I'd like to briefly address the strategic initiatives press release we issued today regarding Elliott Management. As we've discussed over the past several quarters, we remain focused on strengthening execution, expanding profitability, advancing innovation and positioning Align to capitalize on the significant long-term opportunity we see in digital orthodontics and restorative dentistry. The initiatives announced today follow constructive discussions with Elliott are consistent with our objectives and build on work underway across the company.

    在交給 John 之前,我想先簡要說明我們今天就 Elliott Management 發布的策略性措施新聞稿。如同過去幾個季度所討論的,我們仍專注於強化執行力、擴大利潤率、推進創新,並讓 Align 能把握我們在數位矯正與修復牙科領域所看到的顯著長期機會。今日宣布的措施是在與 Elliott 進行建設性討論後提出,與我們的目標一致,並建立在公司各部門已在推進的工作之上。

  • First, as part of our ongoing approach to Board refreshment and governance, we intend to add three new independent directors whose backgrounds are further strengthened the Board's expertise in areas including healthcare technology, innovations, operations and scaling global businesses. We regularly evaluate these skills and experiences represented on the Board to ensure that they align with the evolving needs of our business, and these planned additions reflect that ongoing process.

    第一,作為我們持續推動董事會汰換更新與公司治理的一部分,我們計畫新增三位新的獨立董事,其背景將進一步強化董事會在醫療照護科技、創新、營運以及全球業務擴張等領域的專業能力。我們會定期評估董事會所具備的技能與經驗,以確保其符合業務需求的演進;此次規劃新增成員正反映了這一持續流程。

  • Second, we have initiated a comprehensive strategic and operating model review, supported by a leading global consulting firm to help us further enhance commercial execution, organizational effectiveness, scalability and optimizing resources as we enter our next phase of growth. Importantly, this work is focused on ensuring that we are positioned to capture the significant opportunities ahead while continuing to improve profitability and long-term value creation.

    第二,我們已啟動全面性的策略與營運模式檢視,並由一家全球領先的顧問公司提供支持,以協助我們在進入下一成長階段時,進一步提升商業執行、組織效能、可擴展性並最佳化資源配置。重要的是,這項工作聚焦於確保我們具備掌握未來重大機會的定位,同時持續提升獲利能力與長期價值創造。

  • Third, we increased our 2026 share repurchase commitment, reflecting both the Board's and management's confidence in Align's long-term strategy, competitive position and future cash-generating potential. Finally, we appreciate our discussions with Elliott and look forward to continuing our productive dialogue as we execute the initiatives outlined in the separate press release. The Board and management team remain fully aligned around our strategy, our growth opportunities and our commitment to creating long-term value for shareholders.

    第三,我們提高了 2026 年股票回購承諾,反映董事會與管理團隊對 Align 長期策略、競爭地位以及未來現金創造能力的信心。最後,我們感謝與 Elliott 的討論,並期待在執行另行新聞稿所列措施的同時,持續進行富有成效的對話。董事會與管理團隊在我們的策略、成長機會以及為股東創造長期價值的承諾上,仍保持完全一致。

  • Our strategy remains focused on digital orthodontics and restorative dentistry. We're excited for the opportunity to sharpen execution, improve operating leverage and enhanced governance as we continue to pursue the significant growth opportunities.

    我們的策略仍聚焦於數位矯正與修復牙科。我們對於在持續追求重大成長機會的同時,進一步強化執行、改善營運槓桿並提升公司治理的機會感到振奮。

  • With that, I'll now turn it over to John.

    接下來,我把時間交給 John。

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Thanks, Joe. Now for more details on our Q2 results. Total revenues for the second quarter were $1.0562 billion, up 4.3% from the corresponding quarter a year ago, in line with our Q2 expectations. On a constant currency basis, Q2 revenues were favorably impacted by approximately $12.5 million year-over-year or approximately 1.2%. Q2 Clear Aligner revenues were $870.9 million, up 8.2% year-over-year, primarily due to higher volume, price increases, lower net deferrals and favorable foreign exchange, partially offset by mix shift to lower-priced countries and products and higher discounts.

    謝謝,Joe。接著我將更詳細說明我們第二季(Q2)的業績。第二季總營收為 10.562 億美元,較去年同期成長 4.3%,符合我們對 Q2 的預期。以固定匯率計,Q2 營收年增受惠約 1,250 萬美元,約為 1.2%。Q2 透明牙套(Clear Aligner)營收為 8.709 億美元,年增 8.2%,主要受惠於出貨量增加、漲價、淨遞延(net deferrals)降低以及有利的外匯影響;部分被產品與國家組合轉向較低價格市場與產品,以及折扣增加所抵銷。

  • Favorable foreign exchange impacted Q2 Clear Aligner revenues by approximately $10.6 million or approximately 1.2% year-over-year. Q2 Clear Aligner average per case shipment price of $1,260 increased 0.8% or $10 per case on a year-over-year basis, primarily due to price increases, lower net deferrals, favorable foreign exchange, partially offset by mix shift to lower-priced countries and products and higher discounts. Q2 Systems and Services revenues of $185.3 million were down 10.8% year-over-year.

    有利的外匯對 Q2 透明牙套營收的影響約為 1,060 萬美元,年增約 1.2%。Q2 透明牙套每病例平均出貨價格為 1,260 美元,年增 0.8%(每病例增加 10 美元),主要受惠於漲價、淨遞延降低與有利外匯;部分被組合轉向較低價格國家與產品,以及折扣增加所抵銷。Q2 系統與服務(Systems and Services)營收為 1.853 億美元,年減 10.8%。

  • As Joe discussed, reported revenue was meaningfully affected by the ongoing and strategic evolution of our scanner business model, including greater adoption of lower-cost system configurations and a growing mix of leases and rentals relative to upfront purchases. These options lower the initial cost for customers and are helping us expand patient access to digital diagnostic restorative and orthodontic treatment through iTero scanners, Invisalign clear aligners and the Align Digital Platform.

    如 Joe 所述,受我們掃描器業務模式持續且策略性演進的影響,報告營收受到顯著影響,包括更廣泛採用較低成本的系統配置,以及相較於一次性購買,租賃與出租(leases and rentals)的占比提高。這些選項可降低客戶的初始成本,並協助我們透過 iTero 掃描器、Invisalign 透明牙套與 Align 數位平台,擴大患者取得數位診斷、修復與矯正治療的可近性。

  • During the quarter, placements to new doctors reached a record level and increased double digits year-over-year, while our active scanner installed base grew approximately 11% year-over-year. The growing adoption of lower-priced scanner configurations, including leasing and rental programs, reflects our commitment to expanding customer choice and increasing access to digital dental workflows. By offering a broader range of acquisition options, we are enabling more practices to participate in digital orthodontic and restorative care.

    本季新增醫師的裝機量(placements)創下新高,且年增達雙位數;同時,我們的在用掃描器裝機基礎(active scanner installed base)年增約 11%。較低價格掃描器配置(包含租賃與出租方案)的採用增加,反映我們致力於擴大客戶選擇並提升數位牙科工作流程可近性的承諾。透過提供更廣泛的取得方案,我們讓更多診所能參與數位矯正與修復照護。

  • This is intentional. As the installed base grows, we create opportunities to expand the funnel for orthodontic and restorative treatment, which is better for patients and doctors and carries higher margin and recurring revenue. We are giving up certain economics at the point of sale to expand patient access to treatment, giving doctors the tools they need to provide the treatment and increased volumes and revenues on the back end.

    這是刻意為之。隨著裝機基礎擴大,我們創造機會擴大矯正與修復治療的漏斗(funnel),這對患者與醫師更有利,且具備更高毛利與經常性收入。我們在銷售端放棄部分經濟效益,以擴大患者取得治療的機會,並為醫師提供其所需工具來提供治療,進而在後端帶來更高的量與營收。

  • Q2 Systems and Services revenues reflected lower system ASPs, driven in part by increased adoption of lower-cost configurations and lower scanner wand sales, partially offset by higher systems volume, higher nonsystem sales and favorable foreign exchange. Foreign exchange favorably impacted Q2 Systems and Services revenue revenues by approximately $1.9 million year-over-year or approximately 1%.

    Q2 系統與服務營收反映較低的系統平均售價(ASP),部分由較低成本配置採用增加與掃描器掃描棒(scanner wand)銷售下降所致;部分被系統出貨量增加、非系統(nonsystem)銷售增加以及有利外匯所抵銷。外匯對 Q2 系統與服務營收的有利影響約為 190 萬美元,年增約 1%。

  • Moving on to gross margin. Second quarter overall gross margin was 71.7%, up 1.8 points year-over-year, primarily due to operational efficiencies, tariff refund and higher Clear Aligner ASPs. Q2 overall gross margin was unfavorably impacted by foreign exchange of 0.8 points year-over-year.

    接著談毛利率。第二季整體毛利率為 71.7%,較去年同期提升 1.8 個百分點,主要受惠於營運效率提升、關稅退稅以及透明牙套 ASP 提高。Q2 整體毛利率年比受到外匯不利影響 0.8 個百分點。

  • On a non-GAAP basis, which excludes stock-based compensation, amortization of intangibles related to certain acquisitions, depreciation expense on assets disposed of other than by sale, restructuring and other non-GAAP charges, gross margin for the second quarter was 72.3%, up 1.8 points year-over-year or up approximately 2.6 points at constant currency. Clear Aligner gross margin for the second quarter was 71.4%, up 1.3 points year-over-year, primarily due to higher ASPs and operational efficiencies, partially offset by higher freight costs.

    以非 GAAP 基礎計(排除以股票為基礎之薪酬、與特定收購相關的無形資產攤銷、非出售方式處分資產的折舊費用、重組以及其他非 GAAP 費用),第二季毛利率為 72.3%,較去年同期提升 1.8 個百分點;若以固定匯率計,約提升 2.6 個百分點。第二季透明牙套毛利率為 71.4%,較去年同期提升 1.3 個百分點,主要受惠於 ASP 提高與營運效率提升;部分被運費成本上升所抵銷。

  • Q2 Clear Aligner gross margin was impacted by unfavorable foreign exchange of approximately 0.8 points year-over-year. Margin expansion is increasingly driven by lower refinement rates, improved treatment predictability and higher manufacturing throughput, the result of Align's intentional investment in a data, software and manufacturing-driven flywheel that compounds with scale. Many of our lower-priced product configurations, such as Comp 3-in-3 and DSP Touch-Up, include fewer or no additional aligners and require less manufacturing costs, supporting gross margins and improving cash conversion despite lower upfront pricing.

    Q2 透明牙套毛利率年比受到外匯不利影響約 0.8 個百分點。毛利率擴張愈來愈多由較低的精修(refinement)率、治療可預測性改善以及更高的製造產出(throughput)所驅動,這是 Align 有意投資於以數據、軟體與製造為驅動的飛輪(flywheel)所帶來的成果,並會隨規模擴大而加乘。我們許多較低價格的產品配置(例如 Comp 3-in-3 與 DSP Touch-Up)包含較少或不包含額外牙套,且所需製造成本較低,即使前端定價較低,仍可支撐毛利率並改善現金轉換。

  • The clinical versatility of the Invisalign System allows us to offer configurations such as Zero AA products, enabling doctors to expand Invisalign adoption while meeting patient expectations. These offerings enhance our ability to compete against traditional wires and brackets and lower-priced clear aligner alternatives while allowing us to address a broader range of case complexity and price points without compromising long-term unit economics.

    Invisalign 系統具備臨床上的多樣適用性,使我們能提供如 Zero AA 產品等配置,讓醫師在符合患者期待的同時,擴大 Invisalign 的採用。這些產品與方案提升了我們與傳統鋼線與矯正托槽,以及較低價的透明牙套替代方案競爭的能力,同時讓我們在不犧牲長期單位經濟效益的前提下,涵蓋更廣泛的病例複雜度與價格帶。

  • Systems and Services gross margin for the second quarter was 73.3%, up 3.9 points year-over-year, primarily due to operational efficiencies and tariff refund, partially offset by lower ASPs. On a year-over-year basis, Q2 Systems and Services gross margin was unfavorably impacted from foreign exchange by approximately 0.6 points year-over-year.

    第二季系統與服務(Systems and Services)毛利率為 73.3%,年增 3.9 個百分點,主要受惠於營運效率提升與關稅退稅,部分被較低的平均銷售價格(ASP)所抵銷。以年對年來看,第二季系統與服務毛利率受到外匯影響約 0.6 個百分點,屬不利影響。

  • Q2 operating expenses were $603.4 million, up 10.7% year-over-year. Year-over-year operating expenses increased by $58.3 million, primarily due to UK VAT accrual and higher employee compensation. On a non-GAAP basis, excluding stock-based compensation, legal settlements and contingencies, restructuring and other charges and amortization of acquired intangibles related to certain acquisitions, Q2 '26 non-GAAP operating expenses were $521.5 million, up 4.8% year-over-year.

    第二季營業費用為 6.034 億美元,年增 10.7%。年對年營業費用增加 5,830 萬美元,主要由於英國增值稅(VAT)應計提列以及員工薪酬增加。以非 GAAP 口徑(排除股份基礎給付、法律和解與或有事項、重組及其他費用,以及與特定收購相關之取得無形資產攤銷)計算,26 會計年度第二季非 GAAP 營業費用為 5.215 億美元,年增 4.8%。

  • Our second quarter operating income of $154 million resulted in an operating margin of 14.6%, down approximately 1.5 points year-over-year. Operating margin was unfavorably impacted from foreign exchange by approximately 1.4 points year-over-year. On a non-GAAP basis, which excludes stock-based compensation, legal settlements and contingencies, restructuring and other charges and amortization of acquired intangibles related to certain acquisitions, operating margin for the second quarter was 22.9%, up 1.6 points year-over-year or approximately 3.1 points at constant currency.

    我們第二季營業利益為 1.54 億美元,營業利益率為 14.6%,年減約 1.5 個百分點。營業利益率年對年受到外匯影響約 1.4 個百分點,屬不利影響。以非 GAAP 口徑(排除股份基礎給付、法律和解與或有事項、重組及其他費用,以及與特定收購相關之取得無形資產攤銷)計算,第二季營業利益率為 22.9%,年增 1.6 個百分點;若以固定匯率計算則約增加 3.1 個百分點。

  • The Q2 '26 GAAP effective tax rate was 27.2% compared to 28.2% in the second quarter of 2025. The second quarter GAAP effective tax rate was lower than the second quarter effective tax rate of the prior year primarily due to increased earnings in low tax jurisdictions. Our Q2 '26 non-GAAP effective tax rate was 20%, which reflects our long-term projected tax rate.

    26 會計年度第二季 GAAP 有效稅率為 27.2%,相較 2025 年第二季為 28.2%。第二季 GAAP 有效稅率低於前一年度同期,主要因低稅率司法管轄區的獲利增加。我們 26 會計年度第二季非 GAAP 有效稅率為 20%,反映我們長期預估的稅率。

  • Second quarter net income per diluted share was $1.51, down $0.20 compared to the prior year. On a non-GAAP basis, net income per diluted share was $2.64 for the second quarter, up 6% year-over-year. Our GAAP and non-GAAP EPS was unfavorably impacted by $0.23 on a year-over-year basis due to foreign exchange.

    第二季稀釋後每股淨利為 1.51 美元,較前一年下降 0.20 美元。以非 GAAP 口徑計算,第二季稀釋後每股淨利為 2.64 美元,年增 6%。我們的 GAAP 與非 GAAP 每股盈餘(EPS)年對年因外匯因素受到 0.23 美元的不利影響。

  • We continue to maintain a strong balance sheet and healthy free cash flow, providing flexibility to invest in innovation, support customers and return capital to shareholders. As of June 30, 2026, cash and cash equivalents were $1.1026 billion, up $201.4 million year-over-year. Of the $1.1026 billion balance, $241.1 million was held in the US and $861.5 million was held by our international entities.

    我們持續維持強健的資產負債表與良好的自由現金流,提供投資創新、支援客戶並回饋股東的彈性。截至 2026 年 6 月 30 日,現金及約當現金為 11.026 億美元,年增 2.014 億美元。在 11.026 億美元餘額中,2.411 億美元存放於美國,8.615 億美元由我們的海外實體持有。

  • Align maintains a disciplined capital return program. During Q2 '26, we repurchased approximately 393,400 shares of our common stock at an average price of $169.45 per share for a total of $67 million. These purchases were made pursuant to the $200 million open market repurchase plan announced on April 29, 2026, which we expect to be completed in October of 2026.

    Align 維持嚴謹的資本回饋計畫。在 26 會計年度第二季期間,我們以每股平均 169.45 美元回購約 393,400 股普通股,總金額 6,700 萬美元。上述回購係依據我們於 2026 年 4 月 29 日宣布的 2 億美元公開市場回購計畫進行,預期將於 2026 年 10 月完成。

  • In connection with the expanded value creation initiatives announced today, we now intend to repurchase an aggregate of approximately $400 million to $500 million of our common stock during full year 2026, inclusive of the repurchase under the $200 million plan. As of June 30, 2026, $733.3 million remains available for repurchase of our common stock under our $1 billion stock repurchase program announced in April of 2025.

    配合今日宣布的擴大價值創造措施,我們目前計畫在 2026 全年回購合計約 4 億至 5 億美元的普通股(包含 2 億美元計畫項下的回購)。截至 2026 年 6 月 30 日,在我們於 2025 年 4 月宣布的 10 億美元股票回購計畫下,仍有 7.333 億美元可用於回購普通股。

  • Q2 accounts receivable balance was $1.1484 billion. Our overall days sales outstanding was $98, down 1 day as compared to Q2 of 2025. Cash flow from operations for the second quarter was $192.8 million. Capital expenditures for the second quarter were $35.7 million, primarily related to investments in our manufacturing capacity and facilities. Free cash flow, defined as cash flow from operations minus capital expenditures, amounted to $157.1 million.

    第二季應收帳款餘額為 11.484 億美元。我們整體應收帳款週轉天數(DSO)為 98 天,較 2025 年第二季減少 1 天。第二季營運活動現金流為 1.928 億美元。第二季資本支出為 3,570 萬美元,主要與我們製造產能與設施投資相關。自由現金流(定義為營運活動現金流減去資本支出)為 1.571 億美元。

  • We continue to maintain a strong balance sheet and generate healthy cash flow, providing flexibility to invest in innovation, support customers and return value to shareholders. We remain focused on disciplined capital allocation and long-term value creation.

    我們持續維持強健的資產負債表並產生良好的現金流,提供投資創新、支援客戶並為股東創造回報的彈性。我們仍專注於嚴謹的資本配置與長期價值創造。

  • In summary, our second quarter results reflect continued execution across the business, solid clear aligner performance, disciplined expense management and operational improvements, supported revenue growth in line with our outlook and non-GAAP operating margin above our expectations. Our growth initiatives continue to drive doctor adoption, utilization and patient conversion. While Q2 '26 Systems and Services revenue was below our original expectations, underlying scanner adoption remained healthy, and the reported lower revenues reflects lower price scanners and the transition toward lease and rental models that increased patient access to care by offering a broader range of purchasing options and increasing adoption of our digital scanning technology.

    總結而言,我們第二季的結果反映出公司各面向持續落實執行、透明牙套表現穩健、費用管理嚴謹與營運改善,支撐營收成長符合我們的展望,且非 GAAP 營業利益率高於我們預期。我們的成長計畫持續推動醫師採用、使用率與患者轉換。雖然 26 會計年度第二季系統與服務營收低於我們原先預期,但掃描儀的採用基本面仍然健康;已揭露的較低營收反映較低價格掃描儀的占比提高,以及轉向租賃與出租模式,透過提供更廣泛的購買選項提升患者就醫可近性,並提高我們數位掃描技術的採用。

  • This is a deliberate trade-off on our part. While this model may impact upfront economics and timing of revenue recognition, it enables us to serve more customers and to drive for higher margin treatment revenue and durable long-term growth. Stronger Clear Aligner revenue growth and ASP performance helped offset the near-term impact.

    這是我們刻意做出的取捨。雖然此模式可能影響前期經濟效益與營收認列時點,但可讓我們服務更多客戶,並推動更高毛利的治療營收與更具持續性的長期成長。更強勁的透明牙套營收成長與 ASP 表現,有助於抵銷短期影響。

  • Before I turn to our outlook, I want to provide an update on the UK VAT situation. Following the first-tier Tribunal's 2025 decision that clear aligners qualify as VAT exempt dental prosthesis, we stopped charging VAT to UK customers effective August 1, 2025. On July 7, 2026, the UK Upper Tribunal overturned that decision, determining that clear aligners do not qualify as VAT exempt dental prosthesis. We acknowledge the ruling and will comply with applicable law.

    在我轉入展望之前,我想就英國增值稅(VAT)情況提供最新進展。在第一審法庭(First-tier Tribunal)於 2025 年裁定透明牙套符合 VAT 免稅之牙科義齒(dental prosthesis)後,我們自 2025 年 8 月 1 日起停止向英國客戶收取 VAT。2026 年 7 月 7 日,英國上級法庭(Upper Tribunal)推翻該裁定,認定透明牙套不符合 VAT 免稅之牙科義齒。我們尊重該裁決並將遵循適用法律。

  • Effective September 7, 2026, invoices will include UK VAT at 20% on applicable Invisalign aligners and Vivera retainers. Our list price remain unchanged. As a result of the ruling, we have recorded an estimated liability of approximately $37.5 million, inclusive of interest. We intend to appeal, though the ultimate resolution remains subject to uncertainty.

    自 2026 年 9 月 7 日起,發票將就適用的 Invisalign 牙套與 Vivera 維持器加計 20% 英國 VAT。我們的牌價維持不變。因該裁決影響,我們已認列約 3,750 萬美元的估計負債(含利息)。我們擬提出上訴,但最終結果仍存在不確定性。

  • Now turning to Q3 and fiscal '26 business outlook. Assuming no circumstances occur beyond our control, such as foreign exchange, macroeconomic condition and extended war and changes to currently applicable duties, including tariffs or other fees that could impact our business, we expect Q3 '26 worldwide revenues to be in the range of $1 billion to $1.020 billion, down sequentially from Q2 of '26. We expect Q3 '26 Clear Aligner volume to be up mid-single digits year-over-year and Q3 '26 Clear Aligner ASPs to be down sequentially from geographic mix and foreign exchange.

    接著談第三季與 26 會計年度的業務展望。在假設不發生超出我們控制範圍的情況(例如外匯、總體經濟狀況、戰事延長,以及對目前適用稅費的變更(包括關稅或其他費用)而可能影響我們業務)下,我們預期 26 會計年度第三季全球營收將介於 10.0 億至 10.20 億美元,較 26 會計年度第二季呈季減。我們預期 26 會計年度第三季透明牙套出貨量年增中個位數百分比,且第三季透明牙套 ASP 將因地理組合與外匯因素較第二季呈季減。

  • We expect Q3 '26 Systems and Services revenue to be down sequentially and year-over-year because of Q3 seasonality, alongside a continued mix shift towards lower-priced scanners and our flexible acquisition models, including leasing and rental units and certified preowned offers. We expect Q3 '26 worldwide GAAP gross margin to be 67.5% to 68.5%, down sequentially approximately by 3 to 4 points due to the incurrence of onetime charges expected to be approximately $20 million to $30 million, primarily for accelerated depreciation and restructuring and other charges in Q3 of '26.

    我們預期 2026 會計年度第 3 季(Q3 '26)系統與服務營收將較前一季及較去年同期下滑,原因在於 Q3 的季節性因素,以及產品組合持續轉向較低價位的掃描器與我們更具彈性的取得模式(包括租賃與租用機台,以及認證二手機(certified preowned)方案)。我們預期 Q3 '26 全球 GAAP 毛利率為 67.5% 至 68.5%,較前一季約下降 3 至 4 個百分點,主要因 Q3 '26 預計將發生約 2,000 萬至 3,000 萬美元的一次性費用,主要用於加速折舊、重整以及其他費用。

  • We expect Q3 non-GAAP gross margin to be approximately 71%, down sequentially from lower ASPs, consistent with typical Q3 quarter-over-quarter trends. We expect Q3 '26 GAAP operating margin to be between 13.5% and 15% due to the incurrence of onetime charges expected to be approximately $35 million to $50 million, primarily for restructuring and other charges and accelerated depreciation in Q3 of '26. We expect Q3 '26 non-GAAP operating margin to be approximately 24%.

    我們預期 Q3 非 GAAP 毛利率約為 71%,因平均售價(ASP)下降而較前一季下滑,符合典型 Q3 季對季趨勢。我們預期 Q3 '26 GAAP 營業利益率介於 13.5% 至 15%,主要因 Q3 '26 預計將發生約 3,500 萬至 5,000 萬美元的一次性費用,主要用於重整及其他費用與加速折舊。我們預期 Q3 '26 非 GAAP 營業利益率約為 24%。

  • For fiscal 2026, we expect -- we continue to expect 2026 worldwide revenue growth to be up 3% to 4% year-over-year. Our full year 2026 revenue guidance continues to assume a benefit from foreign exchange that is consistent with the assumptions underlying our initial full year outlook. We expect the effect of foreign exchange to moderate in the remaining quarters, trending towards the full year assumption of approximately 100 basis points.

    就 2026 會計年度而言,我們預期——我們仍預期 2026 年全球營收年增率為 3% 至 4%。我們 2026 全年營收指引仍假設外匯帶來的正面效益,且與我們最初全年展望所依據的假設一致。我們預期外匯影響在剩餘季度將趨於緩和,並朝向全年假設約 100 個基點的水準。

  • We now expect 2026 Clear Aligner volume growth to be up approximately 6% year-over-year and 2026 Clear Aligner ASP to be flat to slightly down from 2025. We now expect 2026 Systems and Services revenue growth to be down 6% to 8% year-over-year as we anticipate a continued mix shift towards lower-priced scanners and more flexible acquisition models in the second half of '26.

    我們目前預期 2026 年透明矯正器(Clear Aligner)出貨量成長約為年增 6%,且 2026 年透明矯正器 ASP 相較 2025 年持平至小幅下滑。我們目前預期 2026 年系統與服務營收年增率將下滑 6% 至 8%,因我們預期在 '26 下半年產品組合將持續轉向較低價位的掃描器與更具彈性的取得模式。

  • We expect our 2026 iTero scanner shipments to be up double digits year-over-year, reflecting continued customer adoption and scanner placements and helping to underpin our second half outlook for Invisalign volumes. We expect 2026 GAAP gross margin to be approximately 70.2% to 70.5%, up year-over-year by approximately 3 points due to the incurrence of onetime charges expected to be approximately $30 million to $40 million, primarily for accelerated depreciation, restructuring and other charges, partially offset by a gain on assets held for sale.

    我們預期 2026 年 iTero 掃描器出貨量將呈現年增雙位數,反映客戶持續採用與設備布建,並有助於支撐我們對下半年 Invisalign 出貨量的展望。我們預期 2026 年 GAAP 毛利率約為 70.2% 至 70.5%,較去年同期約提升 3 個百分點;其中包含預計約 3,000 萬至 4,000 萬美元的一次性費用(主要為加速折舊、重整及其他費用),並部分由待售資產處分利益所抵銷。

  • We expect 2026 non-GAAP gross margin to be up approximately 100 basis points over 2025 non-GAAP gross margin. We expect 2026 GAAP operating margin to be approximately 15.1% to 15.6%, up year-over-year by approximately 2 points due to the incurrence of onetime charges expected to be approximately $90 million to $110 million, primarily related to restructuring and other charges, accelerated depreciation, legal settlements, partially offset by gain on assets held for sale.

    我們預期 2026 年非 GAAP 毛利率將較 2025 年非 GAAP 毛利率提升約 100 個基點。我們預期 2026 年 GAAP 營業利益率約為 15.1% 至 15.6%,較去年同期約提升 2 個百分點;其中包含預計約 9,000 萬至 1.1 億美元的一次性費用,主要與重整及其他費用、加速折舊、法律和解相關,並部分由待售資產處分利益所抵銷。

  • In Q2 '26, we recorded $38 million for Clear Aligner UK VAT liability. We expect 2026 non-GAAP operating margin to be approximately 23.7%, a 100 basis point improvement year-over-year, consistent with our previous guidance. We expect our investments in capital expenditures for fiscal 2026 to be $125 million to $150 million. Capital expenditures primarily relate to technology upgrades, additional manufacturing capacity as well as maintenance.

    在 Q2 '26,我們就透明矯正器英國增值稅(VAT)負債認列了 3,800 萬美元。我們預期 2026 年非 GAAP 營業利益率約為 23.7%,較去年同期改善 100 個基點,與我們先前指引一致。我們預期 2026 會計年度資本支出投資為 1.25 億至 1.5 億美元。資本支出主要與技術升級、增加製造產能以及維護相關。

  • We now expect to repurchase $400 million to $500 million of our common stock in 2026, reflecting the conviction of the Board and management in Align's long-term value. This includes the approximately $133 million of our common stock we expect to repurchase through October 2026.

    我們目前預期在 2026 年回購 4 億至 5 億美元的普通股,反映董事會與管理團隊對 Align 長期價值的信心。其中包含我們預期在 2026 年 10 月前回購約 1.33 億美元的普通股。

  • Before I hand it back to Joe, I want to take a moment to offer some preliminary high-level framing for 2027, especially given the work we are doing to drive growth, cost discipline and margin expansion. To be clear, we are not issuing formal guidance for next year. It's too early, and our strategic and operating model review is still underway. However, we remain laser-focused on executing our strategic plan for profitable revenue growth across our 2 operating segments.

    在我把時間交還給 Joe 之前,我想先花點時間就 2027 年提供一些初步的高層次框架,特別是考量我們正在推動成長、成本紀律與利潤率擴張的相關工作。需要說明的是,我們並未對明年提供正式指引。現在仍為時過早,而且我們的策略與營運模式檢視仍在進行中。不過,我們仍高度聚焦於執行策略計畫,在兩大營運部門實現具獲利性的營收成長。

  • Based on our continued progress and the initiatives we outlined in the strategic initiative press release today, we are comfortable targeting at least the same level of improvement in operating margin in fiscal 2027 on top of the approximately 100 basis points of operating margin improvement we reiterated for fiscal 2026. For fiscal 2027, we currently expect GAAP and non-GAAP operating margin to increase at least approximately 100 basis points year-over-year. We'll share more details after our strategic and operating model review is complete and in conjunction with formal 2027 guidance.

    基於我們持續的進展,以及我們今天在策略倡議新聞稿中所概述的各項措施,我們有信心在 2027 會計年度的營業利益率改善幅度,至少可達到與 2026 會計年度相同的水準;而我們也重申 2026 會計年度營業利益率將改善約 100 個基點。就 2027 會計年度而言,我們目前預期 GAAP 與非 GAAP 營業利益率將至少年增約 100 個基點。待我們完成策略與營運模式檢視後,並配合正式的 2027 年指引,我們將分享更多細節。

  • With that, I'll turn it back over to Joe for closing comments. Joe?

    接下來,我把時間交還給 Joe 做結語。Joe?

  • Joseph Hogan - President, Chief Executive Officer, Director

    Joseph Hogan - President, Chief Executive Officer, Director

  • Thanks, John. As we look at the first half of 2026, we're encouraged by the progress across the business. Through the first six months of the year, we delivered record clear aligner volumes, expanded doctor adoption and utilization, increased scanner placements, improved margins and continued to execute against our strategic priorities. Importantly, we achieved these results in an environment that remains uneven across markets and customer segments, reinforcing the strength of our global business. We saw strong momentum across APAC, EMEA and Latin America, despite the macroeconomic headwinds.

    謝謝,John。回顧 2026 年上半年,我們對公司各面向的進展感到振奮。在今年前六個月,我們創下透明矯正器出貨量新高,擴大醫師採用與使用率、增加掃描器布建、改善利潤率,並持續落實我們的策略優先事項。重要的是,我們是在各市場與客戶區隔仍不均衡的環境下達成這些成果,進一步凸顯我們全球業務的韌性。儘管面臨總體經濟逆風,我們在亞太(APAC)、歐洲中東非洲(EMEA)與拉丁美洲仍看到強勁動能。

  • North America remained relatively stable overall with continued strength in the DSO channel, helping to offset softer retail demand. That said, returning North America retail to consistent growth remains a top priority, and we're working to make that happen. The customer-focused initiatives we have been pursuing, financing solutions, DSP, clinical education and support and DSO collaboration are gaining traction, and we're encouraged by the early results.

    北美整體維持相對穩定,DSO 通路持續強勁,有助於抵銷零售需求較疲弱的影響。儘管如此,讓北美零售回到持續成長仍是首要任務,我們正努力促成此事。我們一直推動的以客戶為中心的各項措施——融資解決方案、DSP、臨床教育與支援,以及與 DSO 的合作——正逐步取得進展,我們也對初步成果感到鼓舞。

  • As we enter the second half of 2026, we believe we are well positioned to build on this momentum. We are entering the important teen treatment season with one of the industry's most comprehensive digital treatment portfolios for growing patients and teens. At the same time, we continue to expand opportunities in adult treatment through innovations that connect oral health, restorative workflows and digital orthodontics, helping doctors incorporate Invisalign treatment into broader patient care discussion.

    展望 2026 年下半年,我們相信已具備良好條件在此動能基礎上再接再厲。我們將迎來重要的青少年治療旺季,並以業界最完整之一、面向成長期患者與青少年的數位治療產品組合迎戰。同時,我們也持續透過創新擴大成人治療機會,將口腔健康、修復工作流程與數位齒顎矯正串聯,協助醫師把 Invisalign 治療納入更廣泛的患者照護討論。

  • Our innovation engine remains a key differentiator and is central to our growth strategy. Business model innovation, patient financing, subscription programs such as DSP, no AA offerings and digital workflow innovation are helping doctors improve patient conversion, increase utilization and grow their practices. Every digital workflow begins with a scan, making scanner adoption an important driver to increasing patient access to orthodontic care and long-term platform growth.

    我們的創新引擎仍是關鍵差異化因素,也是我們成長策略的核心。商業模式創新、患者融資、如 DSP 等訂閱方案、無 AA 方案,以及數位工作流程創新,正協助醫師提升患者轉換率、提高使用率並擴大其診所規模。每一個數位工作流程都始於一次掃描,因此掃描器的採用是提升患者取得齒顎矯正照護機會與平台長期成長的重要驅動因素。

  • As we continue to advance our innovation road map and direct fabrication technologies, we are creating more effective and personalized treatment solutions that improve clinical outcomes, enhance operating efficiency and strengthen the customer experience across orthodontics and restorative dentistry. Our focus remains unchanged: helping doctors treat more patients, expanding patient access to care and advancing digital orthodontics and digital dentistry globally.

    隨著我們持續推進創新藍圖與直接製造(direct fabrication)技術,我們正在打造更有效且更個人化的治療解決方案,以改善臨床結果、提升營運效率,並強化在齒顎矯正與修復牙科領域的客戶體驗。我們的重點始終不變:協助醫師治療更多患者、擴大患者取得照護的機會,並在全球推進數位齒顎矯正與數位牙科。

  • We remain realistic about the environment, but encouraged by our results and ability to address the significant opportunities ahead. Importantly, the combination of our global scale, strong international momentum, continued innovation and an increasing integrated digital platform uniquely positions Align to drive adoption of the Invisalign Clear Aligner and iTero systems and services while creating long-term value for customers, partners, employees and shareholders.

    我們對整體環境仍保持務實態度,但對我們的成果以及把握前方重大機會的能力感到鼓舞。更重要的是,我們的全球規模、強勁的國際動能、持續創新,以及日益整合的數位平台之綜效,使 Align 具備獨特優勢,能推動 Invisalign 隱形矯正器與 iTero 系統及相關服務的採用,同時為客戶、合作夥伴、員工與股東創造長期價值。

  • With that, I want to thank you for your time today. Now I'll turn the call back over to the operator for questions. Operator?

    說到這裡,感謝各位今天撥冗參與。接下來我把電話交回給接線員進行問答。接線員?

  • Operator

    Operator

  • (Operator Instructions) Michael Cherny, Leerink Partners.

    (接線員指示)Michael Cherny,Leerink Partners。

  • Michael Cherny - Equity Analyst

    Michael Cherny - Equity Analyst

  • Maybe if I can just ask a question about the case starts number. Obviously, very strong in the quarter, seemingly talking up your expectation for the rest of the year. As you think about the push and pull of macro/micro and what you're seeing in your different customer bases, what's the biggest level of confidence that's allowing you to get to this higher number given obvious questions broadly in the market about whether or not the consumer is at risk? It seems like a really good number. So just trying to put the pieces together about how do you keep the momentum going.

    也許我先問一個關於病例啟動數(case starts)的問題。本季表現顯然非常強勁,而且看起來你們也在上調對今年其餘時間的預期。當你們思考宏觀/微觀因素的拉扯,以及在不同客戶族群中所觀察到的情況時,在市場普遍擔心消費者是否面臨風險的背景下,是什麼讓你們有最大的信心把目標提高到這個更高的數字?這看起來是一個非常好的數字。所以我想把各個線索拼起來:你們要如何維持這股動能?

  • Joseph Hogan - President, Chief Executive Officer, Director

    Joseph Hogan - President, Chief Executive Officer, Director

  • Michael, when I look at it, we felt really good, obviously, about the Invisalign numbers overall, and that's your inquiry. As we talked about, we have a good mix around the world. It's a strong global business. We see APAC at double-digit growth. We're seeing double-digit growth that we have in Europe in different sections and areas. Our DSO businesses are very strong in North America overall.

    Michael,就我來看,我們對 Invisalign 的整體數字感覺非常好,而這也是你提問的重點。如同我們先前提到的,我們在全球各地的組合配置相當均衡。這是一個強勁的全球性業務。我們看到亞太(APAC)呈現雙位數成長。我們也看到歐洲在不同區塊與地區呈現雙位數成長。我們在北美的 DSO 業務整體表現非常強勁。

  • And so with that kind of a mix, it gives me a lot of confidence in the sense that with macroeconomic headwinds and different things that we can help to compensate that because it's never the same all over the world. So I think the quarter reflects pretty well, that dexterity we've shown in the marketplace.

    因此,有了這樣的組合配置,讓我很有信心:面對宏觀經濟逆風與各種不同因素,我們能在一定程度上加以對沖,因為全球各地的情況從來不會完全一致。所以我認為本季的表現相當能反映我們在市場上展現的那種靈活應變能力。

  • Operator

    Operator

  • Jon Block, Stifel.

    Jon Block,Stifel。

  • Jonathan Block - Analyst

    Jonathan Block - Analyst

  • Maybe I'll pick up where you left off a little bit, Joe. Any signs at the North American, call it, independent sluggishness that is starting to thaw? So I'm excluding the DSOs. What are the green shoots you're looking for? And is there a secret sauce? In other words, can the additional financing options are we hearing more about, there's no comp AA, sort of help turn the tide in coming quarters? Again, specific to that North American independent bucket.

    Joe,我想延續你剛才的話題再追問一下。北美這邊,所謂獨立診所端的疲弱,有沒有任何開始回溫的跡象?我先把 DSO 排除在外。你們在觀察哪些「綠芽」訊號?是否有什麼關鍵配方?換句話說,我們聽到更多的額外分期/融資選項、以及 no comp AA(無 AA 比較基期)之類的因素,是否能在接下來幾季扭轉局勢?同樣地,這題是針對北美獨立診所這個區塊。

  • Joseph Hogan - President, Chief Executive Officer, Director

    Joseph Hogan - President, Chief Executive Officer, Director

  • Yes, Jon, a great question. Look, we just got back from the orthodontic conference that I referenced overall, too. Just -- there's a lot of enthusiasm by that group. Obviously, there are best doctors in North America overall. And John and I have known these doctors for a long period of time. There's a lot of enthusiasm there, but I don't think anyone's counting on the macro to help us one way or another.

    是的,Jon,這是個很好的問題。你看,我們剛從我先前提到的那場矯正年會回來。整體而言,那個族群的熱情非常高。顯然,他們是北美最頂尖的一批醫師。John 和我也認識這些醫師很長一段時間了。那裡的熱情很高,但我不認為有人會指望宏觀環境在某個方向上幫我們一把。

  • What they feel good about is the innovations that we have here, how we can extend. In my script, I talked about the growing patients' piece, when you think about mandibular advancement with occlusive blocks, IPE, there's a huge amount of enthusiasm about that and help us from market share, too. So obviously, DSP has been a big winner, and we continue to try to expand that. The no AA product that you just referenced is just a good fighter out there in the sense of trying to meet a consumer where they are sometimes.

    他們感到樂觀的是我們在這裡推出的創新,以及我們如何把應用延伸出去。在我的講稿裡我提到擴大患者族群這一塊;當你想到下顎前移(mandibular advancement)搭配咬合墊(occlusive blocks)、IPE(牙間去釉),大家對此有非常高的熱情,這也能幫助我們提升市占。所以很明顯,DSP 一直是很大的贏家,我們也會持續嘗試擴大它。你剛提到的 no AA 產品,在某種意義上也是一個很好的競爭工具,因為它能在某些情況下更貼近消費者所處的位置與需求。

  • So overall, I feel good about our portfolio. I feel good about the innovation that we have and how it's being accepted in the marketplace. Our forecast that we just gave here are not reflected any kind of improvement in macro, we're not that smart. We just keep executing in those specific areas of new products and new types of systems to drive that volume.

    總體來說,我對我們的產品組合很有信心。我也對我們的創新以及市場接受度感到樂觀。我們剛給出的預測並沒有反映任何宏觀環境改善的假設——我們沒那麼聰明。我們只是持續在那些新產品與新型系統的特定領域把執行做好,以帶動量的成長。

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • And I would add that patient financing, expanding that patient financing, we are seeing some traction there. We want to continue that. But that helps that potential patient decide if they want to go into treatment.

    我也想補充一點:在患者融資方面,擴大患者融資選項,我們確實看到一些進展。我們希望持續推進。因為這能幫助潛在患者決定是否要開始治療。

  • Jonathan Block - Analyst

    Jonathan Block - Analyst

  • Okay. That's helpful. And the second one is a little bit long. John, I'll sort of go to you. Systems and Services now expected to be down 7% year-over-year at the midpoint.

    好的。這很有幫助。第二個問題會稍微長一點。John,我把問題交給你。系統與服務(Systems and Services)目前預期在年增率的中位數會下滑 7%。

  • I think prior, at least I was flattish. So like that difference of $55 million seems to be made up all Clear Aligner revenues, what, somewhat split between a higher volume assumption and a slightly higher ASP? I guess, one, is that a fair way to sort of define that or categorize that?

    我記得先前至少我的理解是大致持平。所以這大約 5,500 萬美元的差異,看起來是由隱形矯正器(Clear Aligner)營收補上——大概是較高的量假設與略高的 ASP(平均售價)各占一部分?第一個問題是:這樣的描述或分類方式是否合理?

  • And then maybe you can talk on it. The higher ASP surprised at least me for the quarter. It was a little bit above where you were talking $1,260 versus $1,250. And arguably, FX went against you a bit intra-quarter. So what led to that better ASP result that seemingly, you feel comfortable about extrapolating going forward?

    接著也請你談談 ASP。本季較高的 ASP 至少讓我感到意外。它略高於你們先前提到的水準:1,260 美元對比 1,250 美元。而且可以說,本季內匯率(FX)對你們有些不利。那麼,是什麼因素帶來這個更好的 ASP 表現,且看起來你們也有信心把這個趨勢往後外推?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Yes, you're right on your first question. The Systems and Services being down 7% at the midpoint for the year is being offset by the Invisalign volume and stronger ASPs from what we've talked about where you've seen some split that continues in North America, but then growth outside of that to be able to take our volumes in up.

    是的,你第一個問題的理解是正確的。全年在中位數預期系統與服務下滑 7%,會由 Invisalign 的出貨量以及我們所提到的更強 ASP 來抵消;你看到北美仍有一定的分化,但北美以外的成長能把我們的總量推升。

  • When we look at the ASPs, we see some of the benefit in terms of some of the products that coming through where you're seeing some of the products maybe at a slightly higher price, a higher list price, which helps us, that helps our overall ASP. We also get some of the benefit where we're recognizing still a significant amount of revenue even on those 3-in-3, which is our most popular product as well as the no AA product. So we're seeing that ASP come through, and that showed up in our numbers.

    就 ASP 而言,我們看到一些利多來自於部分產品的組合效益:某些產品可能定價略高、牌價(list price)較高,這對我們有利,也有助於整體 ASP。此外,我們在 3-in-3(我們最受歡迎的產品)以及 no AA 產品上,仍能認列相當可觀的收入。因此我們看到 ASP 的提升反映出來,也呈現在本季數字中。

  • And I would also say that maybe when we look at our ortho business in total, when we look at that, we saw some strength there overall, which usually comes with a higher list price as well. So those are the offsets that we see. We're pleased with the ASPs being able to hold to where we're at. And you're right, that does help us as we go into the second half of the year.

    我也會補充:如果我們看整體矯正(ortho)業務,我們確實看到一些整體上的強勁表現,而這通常也會伴隨較高的牌價。這些就是我們所看到的抵消因素。我們對 ASP 能維持在目前水準感到滿意。而你說得沒錯,這確實有助於我們進入下半年。

  • Operator

    Operator

  • Brandon Vazquez, William Blair.

    Brandon Vazquez,William Blair。

  • Brandon Vazquez - Analyst

    Brandon Vazquez - Analyst

  • Maybe I'll ask two because they're kind of -- it's a little bit of a 2-parter, connected. One, I want to ask a little more granular on North America. Can you guys just talk about like -- because we don't know the relative trends, US versus outside of the US. Did things get worse within the quarter within North America? I know there's been a lot of noise, rising gas prices, et cetera. Some channel checks have suggested maybe there were some pockets of weakness. So curious, like what are you seeing in the US specifically?

    我可能會問兩個,因為它們有點——算是相互連結的兩段式問題。第一個,我想更細緻地問一下北美。你們能否談談——因為我們不清楚相對趨勢,美國本土與美國以外的北美地區之間的差異。在北美範圍內,本季進行中是否有變得更差?我知道市場上有很多雜音,例如油價上漲等等。一些通路調查顯示可能有某些區域出現疲弱。所以我想了解:就美國市場本身而言,你們具體看到了什麼?

  • And then the follow-up question that -- maybe for John, how do you think about as you -- with an updated guidance here for Clear Aligners, how do you think about what's baked into that? Like are you taking the exit rate from Q2 and pushing that forward? Just help us understand. The seasonality in the business has been a little lumpy, of course, over the past couple of years. So it's hard to know what Q2 to Q3 usually is. So how are you guys thinking of framing the guidance relative to macro today?

    接著一個追問——可能問 John:在你們更新了 Clear Aligners 的指引之後,你們怎麼看這份指引裡面「已經反映/納入」了哪些假設?例如,你們是把 Q2 的退出率(exit rate)往後延伸套用嗎?請幫我們理解一下。當然,過去幾年這個業務的季節性一直有點不均勻。所以很難知道 Q2 到 Q3 通常會是什麼樣子。那麼相對於當前的總體經濟環境,你們打算如何界定/框架這次的指引?

  • Joseph Hogan - President, Chief Executive Officer, Director

    Joseph Hogan - President, Chief Executive Officer, Director

  • Brandon, it's Joe. I would just start off by saying stable from a North America standpoint. There is a lot of fluctuation when you look at different regions, if you look at the Northeast versus Florida, California, whatever. And I don't want to go into specificity of that. But overall, I would call it stable.

    Brandon,我是 Joe。我先說,從北美的角度來看是穩定的。但如果你看不同地區,例如東北部對比佛羅里達、加州等等,波動其實很大。我不想深入到太具體的細節。但整體而言,我會稱之為穩定。

  • The DSOs continue to grow, as I mentioned in my script, overall, but I would say, basically, what we've seen is no better and no worse than what we've seen before. And obviously, we just keep working on our portfolio, working with the DSOs, all the things we've been having success to try to extend that.

    如同我在講稿裡提到的,DSO 仍在持續成長,整體來看是如此;但我會說,基本上我們看到的情況不比以前更好、也不比以前更差。而且很明顯地,我們會持續優化我們的產品組合、與 DSO 合作,延續我們一直以來成功的各項作法,努力把這些成果擴大。

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • And I would build on that, that stability or those numbers that we see coming out of Q2 when we take guidance, we're looking at the most recent information. We have a good understanding of flow, and that's the best information that we can use for prediction of the next quarter. So we take what we see, like Joe said, it's relatively stable. There's pockets that are better or worse, but that's to be expected. But that's what we use to inform us for our guidance.

    我再補充一下:在我們制定指引時,會以 Q2 最新出來的穩定性或那些數據為基礎,因為我們看的是最新資訊。我們對需求流量(flow)有很好的掌握,而這是我們用來預測下一季最好的資訊。所以我們會採用我們所看到的情況;如 Joe 所說,整體相對穩定。有些區域表現較好或較差,但這是可預期的。而這些就是我們用來形成指引的依據。

  • Operator

    Operator

  • Jason Bednar, Piper Sandler.

    Jason Bednar,Piper Sandler。

  • Jason Bednar - Senior Research Analyst

    Jason Bednar - Senior Research Analyst

  • I'll actually start first on the operating model review. I know it's super early. But are there any obvious areas of optimization that you have in mind? Is everything under consideration across your expense line when we think about like R&D, sales, marketing? Or maybe asked differently, is there anything off limits when we think about your commitment to 100 basis points? Just trying to understand like and think about this review in the context of past restructuring activities for Align.

    我先從營運模式檢視(operating model review)開始問。我知道現在還非常早。但你們腦中是否已經有任何明顯的優化方向?當我們想到研發、銷售、行銷等費用項目時,你們是否會把整條費用線上的所有項目都納入考量?或者換個問法:在你們承諾提升 100 個基點(100 basis points)的前提下,有沒有任何是「不在討論範圍」的?我想理解的是:在 Align 過去重整/重組活動的脈絡下,這次檢視應該如何看待。

  • Joseph Hogan - President, Chief Executive Officer, Director

    Joseph Hogan - President, Chief Executive Officer, Director

  • Jason, Joe. Look, I'll just start off and say our strategy remains intact. In our strategy, we're a growth business. We know that. We're technology-led, the distribution-led, in that sense. But I'm not saying anything is completely off of this. We'll look at across the board and see what makes sense. And it's -- I think it's a good progress, a process for us.

    Jason,我是 Joe。你看,我先說我們的策略仍然不變。在我們的策略裡,我們是一家成長型企業。我們很清楚這一點。我們是以技術為主導、也以通路/分銷為主導的公司。但我不是說任何事情都完全不會被納入檢視。我們會全面檢視,看看哪些做法合理。而且——我認為這對我們來說是一個很好的進展與流程。

  • Also, we picked a really good consultant to work through that has some experience with us also. And so there's a basis for us to work through that. So I just look at this as an opportunity. I think when you look at execution, you want to say where your focus is or whatever, I think it's healthy for the business.

    另外,我們也找了一位非常好的顧問來協助推進,他/他們也有一些與我們合作的經驗。因此我們有一個基礎可以據此往下推進。所以我把這視為一個機會。我認為從執行面來看,你會想釐清你的重點在哪裡等等;我覺得這對企業是健康的。

  • Jason Bednar - Senior Research Analyst

    Jason Bednar - Senior Research Analyst

  • Okay. Fair enough. And then maybe building on that, I thought for 2027, direct fab was supposed to be a margin driver. Is that in addition to this 100 basis points? Is that captured in this 100 basis points?

    好的。可以理解。那再延伸一下:我原本以為到 2027 年,direct fab 應該會是毛利率的推動因素。那是額外加在這 100 個基點之上嗎?還是說已經包含在這 100 個基點裡?

  • I guess, maybe update us on how you think about direct fab within the context of like the updated margin commentary today?

    也請你們更新一下:在今天更新的毛利率評論脈絡下,你們如何看待 direct fab?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Yes. Jason, think of this as inclusive of everything for next year. This is the best view that we wanted to give. As you know, and we've talked about when direct fab scales up, there is that by itself is a negative headwind just as you scale that, just the efficiency and everything else that we need to have both on the resin side as well as the actual production side. But the view that we gave here includes the direct fab. And so the overall 100 basis points or above is inclusive.

    是的。Jason,把它視為涵蓋明年所有因素的整體觀點。這是我們希望提供的最佳視角。如你所知、我們也談過,當 direct fab 擴大規模時,單就擴產過程而言會形成負面逆風,因為在樹脂端以及實際生產端,我們都需要把效率等各方面做到位。但我們在這裡給出的觀點已經包含 direct fab。因此,整體的 100 個基點或以上,是包含在內的。

  • Operator

    Operator

  • Daniel Grosslight, Citi.

    Daniel Grosslight,花旗(Citi)。

  • Daniel Grosslight - Analyst

    Daniel Grosslight - Analyst

  • I wanted to dig a little bit more into the Systems revenue. Obviously, a few moving pieces here. But I'm curious, what's been the biggest surprise versus your initial expectations? Is it the rental adoption, lower ASP, macro pressure? Just what's been the biggest change in how you're thinking about that?

    我想再深入問一下 Systems 的營收。顯然這裡有幾個變動因素。但我很好奇:相較於你們最初的預期,最大的意外是什麼?是租賃採用率、較低的 ASP(平均售價)、總體經濟壓力嗎?你們對這件事的看法,最大的改變是什麼?

  • And maybe more importantly, how should we be thinking about Systems revenue in '27? Will these headwinds be behind us, so we should see a return to growth in '27? Or do you think we'll still see some lingering impacts of mix.

    也許更重要的是:我們應該如何看待 2027 年的 Systems 營收?這些逆風到 2027 年會消退、因此我們應該看到 2027 年恢復成長嗎?還是你們認為產品組合(mix)的影響仍會持續一段時間?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Dan, this is John. Well, first off, we're not guiding on revenue for next year, but I can kind of get to focus on what we've seen so far this year. We certainly do see that mix that we described in the script, where you have doctors that are making decisions on whether they're going to purchase new or perhaps a certified preowned. Or maybe doctors don't want to put so much money upfront and they'll lease or the rent, and you do see that shift happen across, and that certainly shows up in our numbers.

    Dan,我是 John。首先,我們不會對明年的營收提供指引,但我可以聚焦談談今年迄今我們看到的情況。我們確實看到我們在講稿中描述的組合變化:醫師在做決策時,會考慮是要買全新的,或是買認證的二手機(certified preowned)。或者有些醫師不想一次投入那麼多資金,他們會選擇租賃或租用;你確實看到這種轉移在各處發生,而這也確實反映在我們的數字上。

  • And then you also see maybe retail doctors that they don't maybe feel certain, especially in North America, certain about the economy and so on. They pulled back on their spend. But we had a mix -- some favorable mix from a -- at least from a volume standpoint that showed up with DSOs and some of our labs. So you see that coming through in volume.

    另外你也會看到,可能是一些零售型診所醫師,特別是在北美,對經濟等因素不那麼確定。他們就縮減了支出。但我們在組合上——至少從出貨量(volume)的角度——在 DSO 以及我們的一些實驗室客戶那邊看到了一些較有利的組合。所以你會看到這反映在出貨量上。

  • So I would take a step back and say, overall, we're pleased with the volume. The volume is double digits. Our installed base is up double digits. We are expanding the availability to doctors to be able to get new scanners and purchase them or utilize them any which way that they want. And the added piece that's a benefit that we've seen and more so than I've seen in the past is so many of these new scanners that have gone into placement are new doctors, doctors that we don't even sell to right now.

    所以我會退一步說,整體而言我們對出貨量感到滿意。出貨量是雙位數成長。我們的裝機基礎(installed base)也是雙位數成長。我們正在擴大提供給醫師的選項,讓他們能取得新掃描器,並以購買或以任何他們想要的方式使用。另外一個我們看到的、而且比我過去看到的更明顯的好處是:這些新掃描器的許多新增裝機(placement)來自新醫師——也就是我們目前甚至還沒有向其銷售的醫師。

  • And we know that as they start to get more familiar with that scanner and digitize their workflows, it helps us for the broader ecosystem that we have, which includes Invisalign. So we feel good about that volume and that placement, and we're managing the mix as we go forward.

    我們知道,當他們開始更熟悉該掃描器並將工作流程數位化時,這會對我們更廣泛的生態系有幫助,其中也包含 Invisalign。因此我們對這個出貨量與裝機感到樂觀,而我們也會在往前走的過程中管理好產品組合。

  • Daniel Grosslight - Analyst

    Daniel Grosslight - Analyst

  • Got it. Okay. And also, one on just the UK VAT ruling. I think you mentioned that you're not going to change list prices here despite the reimposition of the tax. Does that mean you guys are absorbing the cost here? Or just how does that work from a pricing perspective? And does that impact your profitability targets in the UK?

    了解。好的。另外一題是關於英國 VAT(增值稅)裁定。我想你提到,儘管稅負重新課徵,你們不會在這裡調整牌價(list prices)。這是否表示你們會自行吸收這部分成本?或者從定價角度來看,這會如何運作?這是否會影響你們在英國的獲利目標?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • It is -- just to be clear on that, we're keeping our list prices the same. And then that now that the UK is mandating this VAT, that's essentially being charged to the provider, the customer, and then we pass that through back to HMRC. So it's no impact to us from an ASP standpoint.

    為了把這點講清楚,我們維持名目牌價不變。而現在英國要求課徵這項增值稅(VAT),基本上是向提供者/客戶收取,然後我們再代為轉繳給英國稅務海關總署(HMRC)。因此從平均售價(ASP)的角度來看,對我們沒有影響。

  • Of course, we're going to appeal. And of course, we want to -- we don't think it's good for UK dentistry and healthcare and ultimately, patients who want to go into treatment. But it's a pass-through, and it's something that won't impact our ASPs as a result.

    當然,我們會提出上訴。而且我們當然希望——我們不認為這對英國的牙科與醫療保健,乃至於最終想要接受治療的病患,是件好事。但這是代收代付(pass-through),因此不會因此影響我們的ASP。

  • Operator

    Operator

  • Jeff Johnson, Baird.

    Jeff Johnson,Baird。

  • Jeffrey Johnson - Senior Research Analyst

    Jeffrey Johnson - Senior Research Analyst

  • Thank you. Good afternoon, guys. So I wanted -- one question on third quarter on case shipment growth and your guidance for that. As I look at the 2Q to 3Q comp, it gets about 4.5 points tougher. You just did 7%. You're guiding to mid-single digits for 3Q, so maybe a couple of points of slowing. But on a comp-adjusted basis, a little better.

    謝謝。各位下午好。我想問——關於第三季病例出貨量(case shipment)成長以及你們對此的指引。我看第二季到第三季的比較基期(comp),大約會變得困難4.5個百分點。你們剛做到7%。你們對第三季的指引是中個位數(mid-single digits),所以可能會放緩幾個百分點。但若以調整比較基期後(comp-adjusted)的角度看,反而稍微好一些。

  • So I know you keep saying stable. I know in my surveys, I'm sure you're not seeing much evidence of improvement or anything. But it seems like your guidance is calling for at least on a comp-adjusted basis, a little bit strengthening on that case shipment side in the third quarter. So is that confidence coming from anything you're seeing in that North American market with some of the new financing options like you're talking about? Is it coming from something you're seeing outside the US? Just where are you maybe seeing a little bit, as John referenced earlier, I think green shoots on that?

    所以我知道你們一直說是「穩定」。我知道從我的調查來看,我相信你們也沒有看到太多改善的證據或類似情況。但看起來你們的指引至少在調整比較基期後的口徑下,第三季在病例出貨量這一端是略有轉強。所以這份信心是來自你們在北美市場看到的某些跡象嗎?例如你們提到的一些新的融資選項?還是來自你們在美國以外市場看到的情況?也就是說,你們可能在哪裡看到一些——如John先前提到的——「綠芽」(green shoots)?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Yes. I would say, Jeff, when you look at what we're seeing, we're seeing continued adoption of DSP. DSP is now rolling out to APAC, which we know drives volume through those Touch-Up cases and ultimately gives retainer revenue as well. So we're seeing that. We see the continued rollout of the no AA type products.

    是的。Jeff,我會說,從我們看到的情況來看,我們看到DSP持續被採用。DSP現在也正在推進到亞太(APAC),我們知道這會透過那些Touch-Up病例帶動量能,最終也會帶來維持器(retainer)收入。所以我們看到這點。我們也看到無AA類產品持續推廣。

  • That's really our fastest-growing segment that we see within our portfolio.

    那確實是我們在產品組合中看到成長最快的區塊。

  • As doctors start to use it, they start to learn, kind of almost pay as you go with the refinements that come later. That's been a good adoption that we see. And then we talked about some of the financing, more and more doctors are using this to be able to help get those reluctant patients to -- or potential patients to go into treatment.

    當醫師開始使用後,他們會開始學習,某種程度上就像是後續修正(refinements)採「用多少付多少」(pay as you go)。我們看到這帶來不錯的採用情況。另外我們也談到一些融資方案,越來越多醫師使用這些方案,來協助讓那些猶豫的病患——或潛在病患——進入治療。

  • So we're not relying on economies essentially getting better or really change it at all. It's things that we could do to drive that incremental benefit as we look forward. And I would say broadly, as you look at it, Jeff, we were running about 7% volume on a year-over-year basis in the first half. Second half, it's actually a little bit less than what we ran in the first half. So we're reflective of what we see in the market, but we feel good about the initiatives that we have.

    所以我們並不是仰賴景氣本質上變好,或真的有任何改變。而是我們可以做一些事情,來推動我們展望中那種增量效益。而且我會說,整體來看,Jeff,上半年我們的量在年對年基礎上大約是7%。下半年其實會比上半年略低一些。所以我們的指引反映了我們在市場上看到的情況,但我們對手上的各項措施很有信心。

  • Jeffrey Johnson - Senior Research Analyst

    Jeffrey Johnson - Senior Research Analyst

  • All right. That's helpful. And then maybe one more, just on the scanner and services. And I know the question was just asked. I'm going to try to get at it maybe a slightly different way.

    好。這很有幫助。那再問一個,關於掃描器與服務。我知道剛剛已經有人問過這個問題。我想試著用稍微不同的方式來問。

  • I know you're not guiding to '27 at this point. But are you guys taking a decent amount of medicine upfront here? Have you put some of those pricing programs in, whether it's the CPOs or the lease and rental in that, pretty aggressively to the point that, let's say, 10% or 15% of your new user base is going in that direction? Would we think over the next couple of years, that stays the same? Or is it going to be -- 10% of your user base is adopting those kind of lower-priced models this year and next year, it might be 15 or 20.

    我知道你們目前不會提供到2027年的指引。但你們現在是否在前期就「吞下」了相當程度的影響(take a decent amount of medicine upfront)?你們是否已經把一些定價方案放進去——不論是CPO(採購組織)方案,或是租賃與出租(lease and rental)——而且推得相當積極,以至於例如你們新增用戶中有10%或15%正往那個方向走?那我們是否應該認為未來幾年會維持同樣比例?還是會變成——今年有10%的用戶採用這類較低價格的模式,明年可能變成15%或20%。

  • The next year, 30. And so we have that kind of continued negative mix headwind we should be thinking about, at least conceptually on your scanner and services side in the next couple of few years.

    再下一年,30%。因此在未來幾年,至少在概念上,對你們掃描器與服務端,我們是否應該把這種持續的負向組合(mix)逆風納入考量?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • I would look at it this way, Jeff. I think we're taking this shift, this mix shift that is happening now, and that's really impacted this year. We've called that out. We think we build off of that as we go forward. There's a certain amount of ASP that we have as a result of this, and we build off of that going forward.

    Jeff,我會這樣看。我認為我們正在承接這個轉變、這個正在發生的組合轉移,而這確實在今年造成了影響。我們也已經點出這一點。我們認為隨著往前走,我們會在此基礎上再往上建立。因此我們的ASP會因為這件事而落在某個水準,並在未來以此為基礎持續推進。

  • It's not to say that doctors don't want to continue to lease and rent. But as you go forward with that, as you know, when you start a lease, you might only take 1 or 2 or maybe 3 months of that revenue in that period, but you're going to get that revenue for the next 24, 36 months going forward. So we know that piece of it builds.

    這並不是說醫師不想繼續採用租賃與出租。但如你所知,當你開始一個租賃合約時,在當期你可能只認列1或2個月、也許3個月的收入,但接下來24、36個月你都會持續取得那筆收入。所以我們知道這一塊會逐步累積。

  • And then you're also going to see us do some things around using third-party providers to be able to provide the financing more of a capital lease structure, such that we can now sell to that capital provider at a higher ASP, and then they will provide the leasing arrangement to those customers, and that helps us so that we don't have to take the operating lease on our side. So there's alternatives that we have, but ultimately, we want to be able to drive this business and understand the mix that's going on in the world, but be able to be at a point where we can build off of that as we go forward.

    另外,你也會看到我們在某些方面採用第三方供應商來提供融資,採更偏資本租賃(capital lease)的架構,如此一來我們可以用較高的ASP賣給該資本提供者,然後由他們向客戶提供租賃安排;這也能幫助我們,讓我們不必在我們這邊承擔營業租賃(operating lease)。所以我們有一些替代方案,但最終我們希望能推動這門業務、理解全球正在發生的組合變化,同時也能處在一個位置,讓我們未來可以在此基礎上持續成長。

  • Operator

    Operator

  • Elizabeth Anderson, Evercore ISI.

    Elizabeth Anderson,Evercore ISI。

  • Elizabeth Anderson - Analyst

    Elizabeth Anderson - Analyst

  • As we think about your outperformance on gross margins in the quarter and sort of the updated outlook that you provided, is there something to think about differently between sort of the mix of operating margin expansion in 2026 between gross margin and OpEx? Or should we still think about it kind of 50-50 split that you laid out last quarter?

    當我們思考你們本季毛利率的優於預期表現,以及你們提供的更新展望時,對於2026年營業利益率擴張的組成——毛利率與營業費用(OpEx)之間——是否有什麼需要用不同方式來看待的地方?或者我們仍應該把它視為你們上季所說的大約五五分(50-50 split)?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Yes. I would say, Elizabeth -- this is John. Think of the margin expansion that we've seen, we're very pleased with our op margin expansion. It's primarily driven by the gross margin side. We are seeing a lot of the productivity that we've talked about from last year, some of the productivity improvements around getting closer to our customers, reducing our freight costs, upgrading some of the equipment, using things productively, as well as some of the product mix that's really helping us from a gross margin. The no AA type products, the 3-in-3 and so on, those give us a better gross margin, DSP and so on.

    是的。Elizabeth——我是John。就我們看到的利潤率擴張而言,我們對營業利益率的擴張非常滿意。這主要是由毛利率端所驅動。我們看到許多我們從去年就一直在談的生產力提升:例如更貼近客戶、降低運費成本、升級部分設備、更有效率地使用資產,以及一些產品組合的變化,這些都在毛利率端對我們很有幫助。無AA類產品、3-in-3等等,這些都能帶來較佳的毛利率,DSP等等也是。

  • So I would say it's a combination of -- in that productivity where we're doing things to help from a product standpoint that drives gross margin, as well as a program and initiative standpoint to take costs out to reduce our COGS. And so far this year and the way we're describing this year, it's really been primarily on the gross margin side to generate that 100 basis point improvement in 2026.

    所以我會說這是多重因素的組合——一方面是在生產力上,我們從產品面著手推動毛利率;另一方面也透過各項計畫與倡議來降低成本、減少我們的銷貨成本(COGS)。而就今年迄今以及我們對今年的描述來看,主要是透過毛利率端的改善,來在2026年帶來100個基點的提升。

  • Elizabeth Anderson - Analyst

    Elizabeth Anderson - Analyst

  • Got it. And maybe as a follow-up. Obviously, the question is about the macro forefront. I appreciate what you're saying about sort of the self-generated improvement in the case numbers for the third quarter. Can you give any early commentary sort of on July, particularly regarding the US and sort of how that's trending versus your expectations?

    了解。那我再追問一下。顯然這個問題聚焦在總體環境的前景。我理解你提到第三季病例數(case numbers)有部分是自我驅動的改善。你能否就7月先給一些初步評論,特別是美國市場,以及目前的走勢相較於你們預期如何?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • You know how that goes, Elizabeth. We don't give kind of within the quarter kind of the monthly cadence. I would say, as we've done, we factor in how the quarter plays out, previous quarter, plays out by geography and so on, look at order and intake and then make the best view of that, and that's how we'll guide. But -- that's how we've done it for every quarter and including this third quarter.

    Elizabeth,你也知道一向是怎麼做的。我們不會在季度內提供按月的節奏更新。我會說,正如我們一貫做法,我們會把季度的演變納入考量,參考上一季在不同地區的表現等,檢視訂單與接單(order and intake),然後據此形成我們認為最好的判斷,並以此提供指引。不過——我們每一季都是這樣做的,包括這次第三季也是如此。

  • Operator

    Operator

  • Steven Valiquette, Mizuho Securities.

    Steven Valiquette,瑞穗證券(Mizuho Securities)。

  • Steven Valiquette - Equity Analyst

    Steven Valiquette - Equity Analyst

  • A lot of topics have already been talked about here. But one thing I wanted to come back to was the -- back at the tech innovation meeting that you have with us back in May, you guys highlighted the new Advanced Restorative Treatment program targeting dental labs to get further traction with GPs. Just curious, how much that might be playing a role in the increased guidance for '26? Or does that maybe get more traction for '27? I just want to get an update on how we think about the progression of that.

    很多議題剛剛都已經談過了。但我想回到一點——在你們5月與我們舉行的技術創新會議上,你們強調了新的「先進修復治療」(Advanced Restorative Treatment)計畫,目標是牙科技工所(dental labs),以便在一般牙醫(GPs)端取得更多進展。我想了解,這在你們上調2026年指引中扮演了多大角色?或者這可能要到2027年才會更有動能?我想請你們更新一下,我們應該如何看待這項計畫的推進節奏。

  • Joseph Hogan - President, Chief Executive Officer, Director

    Joseph Hogan - President, Chief Executive Officer, Director

  • Yes. Steve, it's Joe. Look, this is not a huge increase right now. We see a number of labs across the world that are adopting this. They're beginning to integrate it into their workflow, particularly for implants and crown and bridge and those kinds of things were you move teeth first to keep the teeth out of harm's way and save the enamel in that sense.

    是的。Steve,我是Joe。你看,這目前不是一個很大的增量。我們看到全球有不少技工所正在採用這套方案。他們開始把它整合進工作流程中,特別是在植牙以及牙冠與牙橋等情境——也就是你會先移動牙齒,讓牙齒避開風險,從這個角度來說也能保護琺瑯質。

  • So as you look at our 2027, don't count on us leaning way into that in some way, but I feel good about that. I think we're making good progress. There's a good recognition of it. We've integrated much better into our exocad system. So as a lab works with exocad, they can immediately access ClinCheck and different things that would allow them to be able to plan that treatment properly with the -- obviously, with the aligners upfront. So I'm optimistic about it. I'm not forecasting a big increase here right now, but we'll keep you up to date as it continues to grow.

    所以當你看我們2027年的時候,不要指望我們會在某種程度上大幅押注在這上面,但我對此感覺良好。我認為我們正在取得不錯的進展。市場對它的認知度也很好。我們也把它更好地整合進我們的exocad系統。因此當技工所使用exocad時,他們可以立即存取ClinCheck以及其他功能,讓他們能夠正確規劃該治療——當然,是以前端先使用隱形矯正器(aligners)為基礎。所以我對此很樂觀。我現在不會預測這會帶來很大的增量,但隨著它持續成長,我們會持續向各位更新。

  • Operator

    Operator

  • Vik Chopra, BMO.

    Vik Chopra,BMO。

  • Unidentified Participant

    Unidentified Participant

  • So Systems and Scanners, you called out more flexible acquisition models. I'm just curious, how big the proportion of systems placed under lease arrangements or rentals can grow to over time? And how should we think about the economics and payback period of this strategy?

    關於系統與掃描器(Systems and Scanners),你提到更彈性的取得模式。我想了解,隨著時間推移,以租賃或出租方式配置的系統占比,可能成長到多大?以及我們應該如何看待這項策略的經濟性與回收期?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Yes, it's a good question, Vik. Right now, it's a small percentage of our overall revenue. But look, I think, especially in certain markets, it's a big percentage in some of those markets. And I would expect that as doctors and others are under pressure from a capital equipment standpoint, that they might try to lease or rent.

    是的,這是個好問題,Vik。目前它在我們整體營收中占比仍然很小。但你看,我認為特別是在某些市場,這在那些市場中占比其實很高。而我預期,當醫師與其他客戶在資本設備支出方面承受壓力時,他們可能會更傾向於租賃或租用。

  • And from our standpoint, that's a good equation for us because typically then, that price is higher in terms of what they're going to pay us over time. So you don't have to discount as much initially to get a sell-through. They're happy to rent or lease, they keep their monthly payments low.

    從我們的角度來看,這對我們是個不錯的方程式,因為通常他們隨時間支付給我們的總價會更高。因此你不需要在一開始為了促成出貨(sell-through)而做那麼多折扣。他們也樂於用租或租賃的方式,讓每月付款維持在較低水準。

  • In the end, we end up with maybe a higher amount of revenue over time. It's just -- it doesn't come right up front. But again, we're trying to provide access to our digital ecosystem. This is a way to do that with our customers. And we have the portfolio and the resources to be able to provide that.

    最終,我們可能會在更長時間內取得更高的營收總額。只是——它不會立刻在前期一次反映出來。但再說一次,我們正試圖讓客戶更容易進入我們的數位生態系。這是我們與客戶達成這件事的一種方式。而我們也具備產品組合與資源來提供這樣的方案。

  • And when we see that the volume that we put into the market this quarter and to see that the installed base is going up. And like I said earlier, really pleased with the fact that we're selling to doctors that we haven't sold to before. And we know good things happen when that comes about.

    而當我們看到本季投放到市場的量,以及看到裝機基礎(installed base)正在上升。就像我先前說的,我們也非常高興看到我們把產品賣給了以前沒有賣過的醫師。我們知道,一旦出現這種情況,往往就會帶來好的後續效應。

  • Unidentified Participant

    Unidentified Participant

  • Just one quick follow-up, if I could. You called out the North American retail channel. I'm just curious if that were to stabilize or return to growth, how much of a benefit is that to your top line?

    如果可以的話,我再快速追問一個。你提到了北美零售通路。我想了解,如果那邊能夠趨於穩定或恢復成長,對你們營收(top line)的助益會有多大?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Yes, it would certainly be a benefit because right now, it's a drag. So on that retail side, we are laser-focused on all the different initiatives we have to turn that. And we think we can even in this current environment. The economic environment gets better, great. That's a tailwind for us. But we think we can turn this to be positive in this existing environment using all the tools that we've talked about here. And if it does, it certainly would be an improvement to our overall volume that we've described.

    是的,這肯定會有幫助,因為目前它是在拖累。所以在零售端,我們正高度聚焦於所有不同的倡議,來扭轉這個局面。我們認為即使在目前的環境下也能做到。如果經濟環境變好,那很好。那會成為我們的順風。但我們認為,在現有環境下,運用我們在這裡談到的所有工具,也能把它扭轉為正向。而如果真的做到,當然會對我們所描述的整體出貨量帶來改善。

  • Operator

    Operator

  • Erin Wright, Morgan Stanley.

    Erin Wright,摩根士丹利(Morgan Stanley)。

  • Erin Wright - Equity Analyst

    Erin Wright - Equity Analyst

  • So I wanted to dig a little bit more into the Clear Aligner financing initiatives and some of the ones you've launched recently. Do you think -- or how do you think about the rollout of that? Where do you have -- how have you rolled that out? And then also, when do you think it will really move the needle from a conversion perspective? Do you anticipate -- or do you have any sort of early metrics on that front?

    我想再更深入了解一下你們的透明矯正器(Clear Aligner)融資方案,以及你們最近推出的一些措施。你們認為——或你們如何看待這些方案的推廣節奏?你們目前在哪些地方推出——推行進度如何?另外,你們認為它何時會在轉換率(conversion)的角度真正產生顯著影響(move the needle)?你們是否預期——或目前是否已有任何早期指標可以分享?

  • And then I just had a quick follow-up on the UK VAT tax. I think before you lowered the price by 20%, you're saying you're holding the price. But does that mean you're anticipating a volume impact at all? I'm just curious, how you're thinking about that flowing through.

    另外我還有一個關於英國VAT增值稅的快速追問。我記得之前你們把價格下調了20%,但你們現在說會維持價格不變。那是否代表你們預期在量(volume)上會有任何影響?我想了解你們如何看待這件事的傳導影響。

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Okay. I could talk about the UK VAT initially, just on that, we will keep the prices the same that UK VAT will get passed on. So we are looking at what that could mean for volume and making sure we stay close to our customers and so on.

    好的。我可以先談英國VAT。就這點而言,我們會維持相同的價格,英國VAT會轉嫁出去。因此我們正在評估這對量可能意味著什麼,並確保我們與客戶保持緊密溝通等等。

  • They're aware of that change, and we're working closely with them. But like I said, that VAT is a pass-through. So no impact on our ASPs. But you're right, we want to make sure we understand the volume and the trade-offs and so on.

    他們已經知道這項變更,我們也正與他們密切合作。但如我所說,VAT是轉嫁項目(pass-through)。因此不會影響我們的平均售價(ASPs)。不過你說得對,我們希望確保能理解量的影響與各種取捨等等。

  • It maybe gives us a good opportunity to talk about the other portfolio of our products that do come at a lower list price so that maybe there can be some offset if they were used to using some of the more comprehensive unlimited or other products that they can use other parts of our portfolio. So we'll watch that closely.

    這或許也給了我們一個很好的機會,來談談我們產品組合中其他定價較低的產品,這樣如果客戶過去習慣使用較為全面的無限方案或其他產品,他們也許可以改用我們產品組合中的其他部分來做一些抵銷。因此我們會密切觀察。

  • When we think of the Clear Aligner financing or financing for potential patients and so on, we're seeing good traction on this. When we have a doctor that provides a different financing alternatives to external providers, if those providers are very interested in increasing their amount of revenue that they could get from these types of procedures, we're seeing good traction. That means low upfront cost. It means making sure that monthly payment is low enough. It's being able to manage maybe some FICO scores and so on.

    當我們談到 Clear Aligner 的融資,或是針對潛在患者等的融資時,我們看到這方面的推進成效不錯。當有醫師提供不同於外部供應商的多種融資替代方案,而那些供應商也非常有興趣提高他們能從這類療程中取得的營收時,我們就看到很好的進展。這代表前期成本低。也代表要確保每月付款金額夠低。同時也能夠管理可能涉及的 FICO 分數等。

  • So doing things in a way to make sure that we could drive that ultimate patient to go into treatment. And where we've done that, we've seen good adoption. And that's part of what we want to be able to continue to see as we go forward.

    因此,以這樣的方式來做,確保我們能推動最終患者進入治療流程。而在我們做到這些的地方,我們看到良好的採用率。這也是我們希望在未來持續看到的部分。

  • Operator

    Operator

  • Michael Ryskin, Bank of America.

    Michael Ryskin,美國銀行。

  • Michael Ryskin - Analyst

    Michael Ryskin - Analyst

  • Great. Two really quick ones probably. One is -- on the scanner, you touched on sort of the -- some of the awareness and some of the macro CapEx environment impacting docs. But there's also been some incremental competition in the space from a handful of others with launches in the last three to six months. Just wondering if you're seeing that play in the market at all if you're bumping into them a little bit more, if there's been some noise there?

    好的。我可能有兩個很快的問題。第一個是——關於掃描器,你提到一些認知度以及宏觀資本支出(CapEx)環境對醫師的影響。但在過去三到六個月,也有少數競爭者在這個領域推出新產品,帶來一些新增的競爭。想請問你們是否看到這些在市場上有所反映?你們是否更常遇到他們,或是那邊是否有一些雜音?

  • And I'll ask my follow-up at the same time. The ASPs, you kind of have guided to softer ASPs in the second half for some time. You tweaked your ASP guide this quarter, but it seems like you're still guiding for a pretty big step down in 3Q, 4Q just to get -- for the full year, for full year to be flat to down. Pretty meaningful at $40, $50 step down. I know you talked about FX and mix, but it would be great if you could just dig into that a little bit more, break down those two components? And if it is mix, just expand on that a little bit?

    我也同時問一下追問。關於 ASP(平均售價),你們一段時間以來一直指引下半年 ASP 會較疲弱。你們本季調整了 ASP 指引,但看起來仍在指引第三季、第四季會有相當大的下滑——以便讓全年在持平到下滑之間。大約是每次下滑 40 到 50 美元,幅度相當明顯。我知道你們談到匯率(FX)和產品組合(mix),但如果你們能再深入一點,拆解這兩個因素的影響,會很有幫助。如果是組合因素,也請再多展開說明一下?

  • John Morici - Chief Financial Officer, Executive Vice President - Global Finance

    John Morici - Chief Financial Officer, Executive Vice President - Global Finance

  • Yes. Michael, I can take the ASP question first. You certainly have, as we know, going from Q2 to Q3 with China being as big as it is and Europe kind of coming in a lot lower than what it would normally just based on seasonality, you do have a mix effect that hits ASP, and that's why we reflected the ASP reduction going from Q2 to Q3. You have that, we think that it obviously comes back a bit in the fourth quarter because that mix shift then changes. China is lower and as a proportion, and Europe becomes larger. So we have that.

    是的。Michael,我先回答 ASP 的問題。如我們所知,從第二季到第三季,中國的占比很大,而歐洲則因季節性因素而比正常情況低很多,因此確實會有組合效應影響 ASP,這也是我們在從第二季到第三季反映 ASP 下調的原因。我們認為第四季會回升一些,因為那個組合移轉會改變。中國占比降低,而歐洲占比變大。所以我們有這個因素。

  • But there's nothing out of the ordinary. We're going to continue to have DSP and some other products that get rolled out in the second half in APAC and so on. That comes with a lower list price. It's just the reality. It's products that just don't have as high of a list price because they're noncomprehensive cases.

    但沒有任何不尋常的情況。我們在下半年會持續在亞太(APAC)等地推出 DSP 和其他一些產品。這些產品的定價(牌價)會比較低。這就是現實。這些產品的牌價本來就不會那麼高,因為它們不是全面性的病例。

  • So mix shift, that's normal in the third quarter, and then other new products in certain markets like DSP impact the overall ASP.

    因此,組合移轉在第三季是正常的;另外,像 DSP 這類在特定市場推出的新產品,也會影響整體 ASP。

  • Joseph Hogan - President, Chief Executive Officer, Director

    Joseph Hogan - President, Chief Executive Officer, Director

  • And Michael, too, on the scanning side, I'd say I don't see, I'd say, rapidly increased competition. I'd say the composition of the competition has changed pretty substantially over the last few years. We used to see a lot of Medit. We see more shining 3D than we do Medit today. That's all what I'd call the lower end mirror-based scanners.

    另外 Michael,關於掃描端,我會說我沒有看到競爭快速增加。我會說,過去幾年競爭者的組成已經有相當大的變化。我們以前常看到 Medit。而今天我們看到 Shining 3D 比 Medit 更多。這些都屬於我所稱的較低端、以鏡面為基礎的掃描器。

  • When you look at the confocal imaging piece, which is primarily represented by our old technology, which is 5D, and you have that with obviously, with Primescan and 3Shape having that technology, that hasn't changed in a big way either. And lastly, remember, with Lumina too, that's a brand-new technology. It's a different kind of platform. So it gives us a really good competitive position to be able to work through. But overall, this isn't driven what I'd say, by a big change in competition, but we have seen a change in the type of competitors that we're dealing with.

    當你看共焦成像(confocal imaging)這一塊,主要代表的是我們的舊技術,也就是 5D;同時 Primescan 和 3Shape 也有這項技術,這方面也沒有出現很大的變化。最後也請記得,Lumina 也是一項全新的技術。它是一種不同的平台。因此它讓我們具備非常好的競爭地位來推進。但整體而言,我不會說這是由競爭出現重大變化所驅動;不過我們確實看到我們所面對的競爭者類型有所改變。

  • Operator

    Operator

  • Thank you. And we have reached the end of our question-and-answer session. I will now turn the call back over to Shirley Stacy for closing remarks.

    謝謝。我們的問答環節到此結束。我現在把電話交回給 Shirley Stacy 作結語。

  • Shirley Stacy - Vice President, Finance, Corporate and Investor Communications

    Shirley Stacy - Vice President, Finance, Corporate and Investor Communications

  • Well, thank you, everyone, for joining us today. We look forward to meeting with you at upcoming investor conferences and industry meetings. If you have any follow-up questions, please contact Investor Relations. Thanks, and have a great day.

    好的,謝謝各位今天加入我們。我們期待在接下來的投資人會議與產業會議上與各位見面。若您有任何後續問題,請聯絡投資人關係部門。謝謝,祝各位有美好的一天。

  • Operator

    Operator

  • Thank you. This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.

    謝謝。今天的會議到此結束,您現在可以掛斷電話。感謝您的參與。